The most common TEAE of any grade observed with ripretinib was alopecia, regardless of mutational subgroup (KIT exon 11 + 13/14: 66.7%; KIT exon 11 + 17/18: 77.8%); the most common TEAEs with sunitinib in the KIT exon 11 + 13/14 and 11 + 17/18 populations were palmar-plantar erythrodysesthesia syndrome (60.0%) and hypertension (50.0%), respectively (Extended Data Table 4). This evidence concerns the gene KIT and alopecia.